BeiGene, Ltd/$ONC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About BeiGene, Ltd
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.
Ticker
$ONC
Sector
Primary listing
Industry
Biotechnology
Headquarters
Basel, Switzerland
Employees
11,000
ISIN
US07725L1026
Website
BeiGene, Ltd Metrics
BasicAdvanced
$34B
-
-$3.70
0.28
-
Price and volume
Market cap
$34B
Beta
0.28
52-week high
$298.00
52-week low
$174.74
Average daily volume
375K
Financial strength
Current ratio
1.964
Quick ratio
1.645
Long term debt to equity
6.145
Total debt to equity
28.485
Interest coverage (TTM)
-15.99%
Profitability
EBITDA (TTM)
-122.006
Gross margin (TTM)
84.81%
Net profit margin (TTM)
-9.40%
Operating margin (TTM)
-7.10%
Effective tax rate (TTM)
-46.04%
Revenue per employee (TTM)
$380,000
Management effectiveness
Return on assets (TTM)
-3.22%
Return on equity (TTM)
-11.44%
Valuation
Price to revenue (TTM)
7.367
Price to book
8.96
Price to tangible book (TTM)
9.09
Price to free cash flow (TTM)
-127.93
Free cash flow yield (TTM)
-0.78%
Free cash flow per share (TTM)
-226.96%
Growth
Revenue change (TTM)
51.16%
Earnings per share change (TTM)
-51.11%
3-year revenue growth (CAGR)
68.23%
10-year revenue growth (CAGR)
79.79%
3-year earnings per share growth (CAGR)
-43.48%
10-year earnings per share growth (CAGR)
1.21%
Bulls say / Bears say
BeiGene's BRUKINSA® (zanubrutinib) has been approved in over 70 markets for treating diverse B-cell malignancies, exemplifying the strength of their R&D program and reinforcing their commitment to delivering transformative medicines globally. (beigene.com)
The European Commission approved BeiGene's TEVIMBRA® as a monotherapy for adults with unresectable, locally advanced, or metastatic esophageal squamous cell carcinoma after prior platinum-based chemotherapy, expanding their oncology portfolio in Europe. (benzinga.com)
BeiGene's decision to regain full rights to develop, manufacture, and commercialize TEVIMBRA® (tislelizumab) from Novartis allows the company to accelerate its plans and reach more patients worldwide without royalty obligations. (benzinga.com)
The discontinuation of the ociperlimab (BGB-A1217) clinical development program following a Phase 3 trial's futility analysis indicates potential setbacks in BeiGene's pipeline development. (stocktitan.net)
Insider selling activity, such as the sale of 5,000 shares by insider Lai Wang, may raise concerns about internal confidence in the company's future performance. (marketbeat.com)
The mutual agreement to conclude the partnership with NewBridge Pharmaceuticals for BRUKINSA® in the Middle East and Africa could impact BeiGene's market presence and revenue in those regions. (stocktitan.net)
Data summarised monthly by Lightyear AI. Last updated on 10 Jul 2025.
BeiGene, Ltd News
AllArticlesVideos
BeOne Medicines to Announce Second Quarter 2025 Financial Results on August 6
Business Wire·2 days ago
European Commission Approves TEVIMBRA® in Combination with Chemotherapy as a First-Line Treatment for Nasopharyngeal Carcinoma
Business Wire·1 week ago
Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development
Business Wire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for BeiGene, Ltd stock?
BeiGene, Ltd (ONC) has a market cap of $34B as of July 18, 2025.
What is the P/E ratio for BeiGene, Ltd stock?
The price to earnings (P/E) ratio for BeiGene, Ltd (ONC) stock is 0 as of July 18, 2025.
Does BeiGene, Ltd stock pay dividends?
No, BeiGene, Ltd (ONC) stock does not pay dividends to its shareholders as of July 18, 2025.
When is the next BeiGene, Ltd dividend payment date?
BeiGene, Ltd (ONC) stock does not pay dividends to its shareholders.
What is the beta indicator for BeiGene, Ltd?
BeiGene, Ltd (ONC) has a beta rating of 0.28. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.